Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics director Gary A. Lyons received new equity awards as part of his board compensation. He was granted 4,000 shares of common stock at no cost under the company’s 2018 Equity Incentive Plan for non-employee directors, increasing his direct holdings to 61,500 shares.
Lyons was also granted stock options for 12,000 shares of common stock at an exercise price of $42.26 per share, expiring in 2036. The equity award vests over a one year period, making this a routine, compensation-related acquisition rather than an open-market purchase.
Travere Therapeutics, Inc. director Timothy Coughlin reported receiving equity compensation consisting of common shares and stock options. On May 19, 2026, he was granted 4,000 shares of Common Stock, increasing his direct holdings to 56,250 shares. He was also granted stock options for 12,000 shares of Common Stock at an exercise price of $42.26 per share, exercisable starting May 19, 2027 and expiring on May 19, 2036. The filing notes these are automatic equity grants under Travere’s 2018 Equity Incentive Plan for non-employee director compensation, with the equity award vesting over one year.
Travere Therapeutics director Suzanne Louise Bruhn received new equity awards as part of the company’s non-employee director compensation program. She was granted 4,000 shares of common stock, bringing her direct holdings to 32,750 shares after the transaction. She also received stock options covering 12,000 shares of common stock at an exercise price of $42.26 per share. The filing states these awards were automatic grants under Travere’s 2018 Equity Incentive Plan and that the equity award vests over a one-year period.
Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.
Travere Therapeutics director Roy D. Baynes received new equity compensation awards. He was granted 4,000 shares of common stock at no cost and a stock option covering 12,000 shares with a strike price of $42.26 per share.
The awards were made as an automatic equity grant under Travere’s 2018 Equity Incentive Plan pursuant to the non-employee director compensation program. The equity award vests over one year, and following the stock grant Baynes directly holds 41,500 shares of common stock.
Travere Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2018 Equity Incentive Plan to authorize an additional 3,000,000 shares of common stock for equity awards. All ten director nominees were elected, executive compensation received advisory approval, and stockholders indicated a preference for annual advisory votes on pay. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Travere Therapeutics, Inc. director Timothy Coughlin reported an open-market sale of 3,250 shares of common stock at $43.49 per share. The transaction took place on May 15, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan. After the sale, he directly holds 52,250 shares.
Armistice Capital and Steven Boyd report beneficial ownership of 4,897,417 shares of Travere Therapeutics common stock (5.27%) via a joint Schedule 13G filing. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares, and Mr. Boyd may be deemed to beneficially own them as managing member. The Master Fund disclaims beneficial ownership arising solely from its inability to vote or dispose of the shares under its Investment Management Agreement with Armistice Capital.
Travere Therapeutics completed a registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032. The notes are senior unsecured, pay 0.50% interest semi-annually, and mature on May 15, 2032, unless earlier repurchased, redeemed or converted.
The initial conversion rate is 15.4078 shares per $1,000 principal (conversion price about $64.90 per share), with a maximum of 11,729,182 shares issuable based on an initial maximum conversion rate of 22.3413. Travere estimates net proceeds of about $508.5 million.
The company intends to use roughly $350.9 million of the proceeds to repurchase about $221.4 million principal of its outstanding 2.25% senior convertible notes due 2029 and will use the remaining proceeds for general corporate purposes, including commercialization, R&D, capital expenditures, working capital and administrative expenses.
Travere Therapeutics is offering $475,000,000 aggregate principal amount of 0.50% convertible senior notes due 2032, with an underwriter option for an additional $50,000,000. The notes pay 0.50% interest, mature on May 15, 2032, and have an initial conversion rate of 15.4078 shares per $1,000 (approximate conversion price $64.90 per share). Conversions are permitted only upon specified stock-price, note-trading-price, corporate-event or redemption conditions and, if converted, will be settled in cash, shares or a combination at the company’s election. Travere expects to use a portion of net proceeds to repurchase part of its 2.25% convertible senior notes due 2029 and the remainder for general corporate purposes. The offering is not intended to be listed and settlement is expected on or about May 11, 2026.